The overarching goal of the Macias lab is to gain basic mechanistic insights into clinically relevant actionable molecular targets with the eventual goal of aiding to reduce prostate cancer-specific mortality.
Our group integrates human cancer genomic data, functional genomic loss of function screens and pre-clinical in vitro and in vivo mouse models in order to identify, prioritize and validate potential therapeutic targets. Recently, we conducted a functional genomic kinome screen in obese and calorie restricted mice that identified various orphan kinases that are essential for tumor growth in an obese and lean host environment. We are steadily adapting drug development discovery capabilities and lead compound optimization strategies for increased target engagement, efficacy and drug like properties via collaboration with medicinal chemists and structural biologists. In parallel, we are conducting basic mechanistic studies to determine the mechanism of action, including live cell imaging phenotypic gain and loss of function genetic studies and various omic approaches.
Assistant Professor in Pathology in the School of Medicine
2021 School of Medicine
Assistant Research Professor of Cell Biology in the School of Medicine
2022 School of Medicine
Member of the Duke Cancer Institute in the School of Medicine
2018 School of Medicine
2007 North Carolina State University
Publications, Grants & Awards
Offices & Contact
27710 DUMC 2626, 571 Research Drive Msrb-1